112,904 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 112,904 shares of the company’s stock, valued at approximately $629,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Proficio Capital Partners LLC boosted its stake in 4D Molecular Therapeutics by 100.0% during the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company’s stock worth $111,000 after buying an additional 10,000 shares in the last quarter. Marquette Asset Management LLC bought a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth about $116,000. Point72 Asset Management L.P. bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $166,000. M&T Bank Corp boosted its position in shares of 4D Molecular Therapeutics by 98.9% during the 4th quarter. M&T Bank Corp now owns 37,487 shares of the company’s stock valued at $209,000 after acquiring an additional 18,639 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd increased its stake in 4D Molecular Therapeutics by 81.3% in the third quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock valued at $265,000 after acquiring an additional 11,002 shares during the period. Institutional investors own 99.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on FDMT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, March 22nd. Morgan Stanley reduced their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research note on Monday, January 13th. Leerink Partners dropped their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Chardan Capital cut their price target on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Finally, Bank of America decreased their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.71.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT opened at $2.77 on Monday. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.67 and a 52-week high of $29.27. The stock has a market cap of $128.26 million, a PE ratio of -0.97 and a beta of 2.89. The firm has a 50-day moving average of $4.42 and a 200-day moving average of $6.51.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). As a group, analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.